<DOC>
	<DOCNO>NCT01719367</DOCNO>
	<brief_summary>Atrial fibrillation ( AF ) , common sustain heart rhythm disorder , become increasingly prevalent Western world . The number people AF United States project roughly double year 2050 , estimate 6-12 million . For many patient AF , rate control atrioventricular ( AV ) node blocker widely accept therapeutic strategy . These agent control heart rate , thus prevent symptom systolic heart failure associate tachycardia due rapid ventricular response AF . Beta-blockers widely accept first line agent rate control AF , especially patient concomitant hypertension ( HTN ) , coronary artery disease , cardiomyopathy , heart failure ( HF ) . As class , beta-blockers among commonly prescribe cardiovascular medication . Among patient AF treat beta-blockers , heart rate ( HR ) response varies substantially . Sometimes , adequate rate control achieve titration beta-blocker dose ; frequently , additional AV nodal blocker and/or digoxin necessary . In case , adequate rate control achieve even simultaneous use multiple AV nodal blocker , necessitate mechanical ablation AV node permanent pacemaker implantation . Patient-specific variable influence response beta-blockers include comorbid condition , weight , age , level physical activity . Ethnic difference response beta-blockers treatment HTN HF well-described . However , contribution genetic variant beta-blocker efficacy AF unknown . We propose study , use candidate gene approach , effect genetic variant heart rate response beta-blockade patient AF .</brief_summary>
	<brief_title>Genetically Determined Response Atenolol Patients With Persistent Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<criteria>Subjects must least 18 year age . Subjects must history persistent AF currently treat rate control strategy . Subjects willing give write , informed consent . Subjects must willing able participate exercise protocol . New York Heart Association Class III IV heart failure . A history heart failure induce tachyarrhythmia . A history coronary artery disease presence least one following : Canadian Class III IV angina . Recent myocardial infarction , coronary artery bypass grafting , percutaneous coronary intervention within 6 month . Severe renal hepatic impairment . Subjects clinically significant allergy/intolerance atenolol , include history betablocker induce bronchospasm . Females pregnant nursing . History severe AV node dysfunction/pacemaker dependence . Subjects systolic blood pressure &lt; 90 mm Hg rest VR &lt; 50 &gt; 120 per minute day study . Patients currently take VaughanWilliams Class I III antiarrhythmic drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Baseline ( pre-atenolol )</keyword>
	<keyword>Post-atenolol</keyword>
</DOC>